Since the nature of the NF-κB target genes, often associated with pro-tumor pathways, the main therapeutic approaches are essentially aimed to its inhibition (Davis et al., 1999; Adams, 2001; Pikarsky and Ben-Neriah, 2006; Arora et al., 2014; Nomura et al., 2016). Here, NFKB1 is linked to neoplasm.